Huahai Pharmaceuticals hydrochloride sheet was approved by the U.S. FDA No.

Hydrochloric acid methyl ate tablets are mainly used to treat minor brain dysfunction attention deficit disorder (hyperactivity syndrome in children) and so on.hydrochloride sheet was developed by Novartis and first listed in the United States in 1975.at present, in the United States, the main manufacturers of acetate tablets are Camber Pharm, Mallinckrodt, etc. ;the drug had sales in the U.S. market for about $54 million in 2019 (data from the IMS database), and domestic sales data on methyl hydrochloride tablets have not been queried from the relevant database.this acetate tablet salinate has been approved by the U.S. FDA, marking Huahai Pharmaceuticals has the qualifications to sell the product in the U.S. market.announcement also revealed that, so far, Huahai Pharmaceuticals has invested about 8.4 million yuan in research and development costs in the hydrochloric acid methyl ester sheet project..